Compare PERI & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | BWAY |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 450.8M |
| IPO Year | 2005 | N/A |
| Metric | PERI | BWAY |
|---|---|---|
| Price | $8.74 | $12.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $14.75 | $13.25 |
| AVG Volume (30 Days) | ★ 344.1K | 89.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.95 | $314.08 |
| Revenue Next Year | $1.07 | $23.37 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $7.84 |
| 52 Week High | $11.44 | $26.63 |
| Indicator | PERI | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 24.75 |
| Support Level | $8.21 | $11.44 |
| Resistance Level | $9.57 | $13.63 |
| Average True Range (ATR) | 0.28 | 1.15 |
| MACD | 0.05 | -1.40 |
| Stochastic Oscillator | 56.12 | 7.28 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.